Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116


Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer.

Dancy JG, Wadajkar AS, Connolly NP, Galisteo R, Ames HM, Peng S, Tran NL, Goloubeva OG, Woodworth GF, Winkles JA, Kim AJ.

Sci Adv. 2020 Jan 15;6(3):eaax3931. doi: 10.1126/sciadv.aax3931. eCollection 2020 Jan.


Leveraging Surface Plasmon Resonance to Dissect the Interfacial Properties of Nanoparticles: Implications for Tissue Binding and Tumor Penetration.

Wadajkar AS, Dancy JG, Carney CP, Hampton BS, Ames HM, Winkles JA, Woodworth GF, Kim AJ.

Nanomedicine. 2019 Aug;20:102024. doi: 10.1016/j.nano.2019.102024. Epub 2019 Jun 6.


Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma.

Harder BG, Blomquist MR, Wang J, Kim AJ, Woodworth GF, Winkles JA, Loftus JC, Tran NL.

Front Oncol. 2018 Oct 23;8:462. doi: 10.3389/fonc.2018.00462. eCollection 2018. Review.


Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.

Roberts NB, Alqazzaz A, Hwang JR, Qi X, Keegan AD, Kim AJ, Winkles JA, Woodworth GF.

J Neurooncol. 2018 Dec;140(3):497-507. doi: 10.1007/s11060-018-2979-1. Epub 2018 Aug 21.


The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.

Hersh DS, Harder BG, Roos A, Peng S, Heath JE, Legesse T, Kim AJ, Woodworth GF, Tran NL, Winkles JA.

Neuro Oncol. 2018 Sep 3;20(10):1321-1330. doi: 10.1093/neuonc/noy063.


EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.

Roos A, Dhruv HD, Peng S, Inge LJ, Tuncali S, Pineda M, Millard N, Mayo Z, Eschbacher JM, Loftus JC, Winkles JA, Tran NL.

Mol Cancer Res. 2018 Jul;16(7):1185-1195. doi: 10.1158/1541-7786.MCR-18-0125. Epub 2018 May 3.


Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.

Hersh DS, Peng S, Dancy JG, Galisteo R, Eschbacher JM, Castellani RJ, Heath JE, Legesse T, Kim AJ, Woodworth GF, Tran NL, Winkles JA.

J Neurooncol. 2018 Jun;138(2):241-250. doi: 10.1007/s11060-018-2799-3. Epub 2018 Feb 16.


MR-guided transcranial focused ultrasound safely enhances interstitial dispersion of large polymeric nanoparticles in the living brain.

Hersh DS, Anastasiadis P, Mohammadabadi A, Nguyen BA, Guo S, Winkles JA, Kim AJ, Gullapalli R, Keller A, Frenkel V, Woodworth GF.

PLoS One. 2018 Feb 7;13(2):e0192240. doi: 10.1371/journal.pone.0192240. eCollection 2018.


Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma.

Connolly NP, Shetty AC, Stokum JA, Hoeschele I, Siegel MB, Miller CR, Kim AJ, Ho CY, Davila E, Simard JM, Devine SE, Rossmeisl JH, Holland EC, Winkles JA, Woodworth GF.

Sci Rep. 2018 Jan 19;8(1):1180. doi: 10.1038/s41598-018-19451-6.


Decreased non-specific adhesivity, receptor targeted (DART) nanoparticles exhibit improved dispersion, cellular uptake, and tumor retention in invasive gliomas.

Wadajkar AS, Dancy JG, Roberts NB, Connolly NP, Strickland DK, Winkles JA, Woodworth GF, Kim AJ.

J Control Release. 2017 Dec 10;267:144-153. doi: 10.1016/j.jconrel.2017.09.006. Epub 2017 Sep 5.


Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer.

Connolly NP, Stokum JA, Schneider CS, Ozawa T, Xu S, Galisteo R, Castellani RJ, Kim AJ, Simard JM, Winkles JA, Holland EC, Woodworth GF.

PLoS One. 2017 Mar 30;12(3):e0174557. doi: 10.1371/journal.pone.0174557. eCollection 2017.


Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.

Roos A, Dhruv HD, Mathews IT, Inge LJ, Tuncali S, Hartman LK, Chow D, Millard N, Yin HH, Kloss J, Loftus JC, Winkles JA, Berens ME, Tran NL.

Oncotarget. 2017 Feb 14;8(7):12234-12246. doi: 10.18632/oncotarget.14685.


TWEAK activation of the non-canonical NF-κB signaling pathway differentially regulates melanoma and prostate cancer cell invasion.

Armstrong CL, Galisteo R, Brown SA, Winkles JA.

Oncotarget. 2016 Dec 6;7(49):81474-81492. doi: 10.18632/oncotarget.13034.


Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.

Wadajkar AS, Dancy JG, Hersh DS, Anastasiadis P, Tran NL, Woodworth GF, Winkles JA, Kim AJ.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Jul;9(4). doi: 10.1002/wnan.1439. Epub 2016 Nov 4. Review.


Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma.

Roberts NB, Wadajkar AS, Winkles JA, Davila E, Kim AJ, Woodworth GF.

Oncoimmunology. 2016 Aug 19;5(9):e1208876. eCollection 2016. Review.


Emerging Applications of Therapeutic Ultrasound in Neuro-oncology: Moving Beyond Tumor Ablation.

Hersh DS, Kim AJ, Winkles JA, Eisenberg HM, Woodworth GF, Frenkel V.

Neurosurgery. 2016 Nov;79(5):643-654. Review.


Non-specific binding and steric hindrance thresholds for penetration of particulate drug carriers within tumor tissue.

Dancy JG, Wadajkar AS, Schneider CS, Mauban JRH, Goloubeva OG, Woodworth GF, Winkles JA, Kim AJ.

J Control Release. 2016 Sep 28;238:139-148. doi: 10.1016/j.jconrel.2016.07.034. Epub 2016 Jul 25.


Pulsed ultrasound expands the extracellular and perivascular spaces of the brain.

Hersh DS, Nguyen BA, Dancy JG, Adapa AR, Winkles JA, Woodworth GF, Kim AJ, Frenkel V.

Brain Res. 2016 Sep 1;1646:543-550. doi: 10.1016/j.brainres.2016.06.040. Epub 2016 Jun 28.


Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.

Hersh DS, Wadajkar AS, Roberts N, Perez JG, Connolly NP, Frenkel V, Winkles JA, Woodworth GF, Kim AJ.

Curr Pharm Des. 2016;22(9):1177-1193. Review.


Surface plasmon resonance as a high throughput method to evaluate specific and non-specific binding of nanotherapeutics.

Schneider CS, Bhargav AG, Perez JG, Wadajkar AS, Winkles JA, Woodworth GF, Kim AJ.

J Control Release. 2015 Dec 10;219:331-344. doi: 10.1016/j.jconrel.2015.09.048. Epub 2015 Sep 28. Review.


The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.

Perez JG, Tran NL, Rosenblum MG, Schneider CS, Connolly NP, Kim AJ, Woodworth GF, Winkles JA.

Oncogene. 2016 Apr 28;35(17):2145-55. doi: 10.1038/onc.2015.310. Epub 2015 Aug 24. Review.


Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells.

Schneider CS, Perez JG, Cheng E, Zhang C, Mastorakos P, Hanes J, Winkles JA, Woodworth GF, Kim AJ.

Biomaterials. 2015 Feb;42:42-51. doi: 10.1016/j.biomaterials.2014.11.054. Epub 2014 Dec 13.


The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion.

Cheng E, Whitsett TG, Tran NL, Winkles JA.

Mol Cancer Res. 2015 Mar;13(3):575-83. doi: 10.1158/1541-7786.MCR-14-0411. Epub 2014 Nov 12.


Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.

Zhou H, Mohamedali KA, Gonzalez-Angulo AM, Cao Y, Migliorini M, Cheung LH, LoBello J, Lei X, Qi Y, Hittelman WN, Winkles JA, Tran NL, Rosenblum MG.

Mol Cancer Ther. 2014 Nov;13(11):2688-705. doi: 10.1158/1535-7163.MCT-14-0346. Epub 2014 Sep 19.


Regulation of fibroblast growth factor-inducible 14 (Fn14) expression levels via ligand-independent lysosomal degradation.

Gurunathan S, Winkles JA, Ghosh S, Hayden MS.

J Biol Chem. 2014 May 9;289(19):12976-88. doi: 10.1074/jbc.M114.563478. Epub 2014 Mar 20.


TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic.

Cheng E, Armstrong CL, Galisteo R, Winkles JA.

Front Immunol. 2013 Dec 23;4:473. doi: 10.3389/fimmu.2013.00473.


Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation.

Dhruv HD, Whitsett TG, Jameson NM, Patel F, Winkles JA, Berens ME, Tran NL.

Carcinogenesis. 2014 Jan;35(1):218-26. doi: 10.1093/carcin/bgt289. Epub 2013 Aug 23.


Molecular determinants of lung cancer metastasis to the central nervous system.

Whitsett TG, Inge LJ, Dhruv HD, Cheung PY, Weiss GJ, Bremner RM, Winkles JA, Tran NL.

Transl Lung Cancer Res. 2013 Aug;2(4):273-83. doi: 10.3978/j.issn.2218-6751.2013.03.12. Review.


TWEAK-independent Fn14 self-association and NF-κB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain.

Brown SA, Cheng E, Williams MS, Winkles JA.

PLoS One. 2013 Jun 4;8(6):e65248. doi: 10.1371/journal.pone.0065248. Print 2013.


Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.

Zhou H, Hittelman WN, Yagita H, Cheung LH, Martin SS, Winkles JA, Rosenblum MG.

Cancer Res. 2013 Jul 15;73(14):4439-50. doi: 10.1158/0008-5472.CAN-13-0187. Epub 2013 May 30.


The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.

Asrani K, Keri RA, Galisteo R, Brown SA, Morgan SJ, Ghosh A, Tran NL, Winkles JA.

Mol Cancer Res. 2013 Apr;11(4):393-404. doi: 10.1158/1541-7786.MCR-12-0542. Epub 2013 Feb 1.


New insights into the functional consequences of ephrin A3 mutations in non-small cell lung cancer.

Whitsett TG, Loftus JC, Winkles JA, Tran NL.

Transl Lung Cancer Res. 2013 Feb;2(1):3-5. doi: 10.3978/j.issn.2218-6751.2012.10.05. No abstract available.


The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.

Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, Winkles JA, Rosenblum MG.

J Invest Dermatol. 2013 Apr;133(4):1052-62. doi: 10.1038/jid.2012.402. Epub 2012 Nov 29.


Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.

Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, Hostetter G, Weiss GJ, Kingsley CB, Loftus JC, Bremner R, Tran NL, Winkles JA.

Am J Pathol. 2012 Jul;181(1):111-20. doi: 10.1016/j.ajpath.2012.03.026. Epub 2012 May 23. Erratum in: Am J Pathol. 2012 Nov;181(5):1889.


Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-induced migration and invasion of glioblastoma cells.

Fortin SP, Ennis MJ, Schumacher CA, Zylstra-Diegel CR, Williams BO, Ross JT, Winkles JA, Loftus JC, Symons MH, Tran NL.

Mol Cancer Res. 2012 Jul;10(7):958-68. doi: 10.1158/1541-7786.MCR-11-0616. Epub 2012 May 9.


LRAD3, a novel low-density lipoprotein receptor family member that modulates amyloid precursor protein trafficking.

Ranganathan S, Noyes NC, Migliorini M, Winkles JA, Battey FD, Hyman BT, Smith E, Yepes M, Mikhailenko I, Strickland DK.

J Neurosci. 2011 Jul 27;31(30):10836-46. doi: 10.1523/JNEUROSCI.5065-10.2011.


Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.

Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, Rosenblum MG, Winkles JA.

Mol Cancer Ther. 2011 Jul;10(7):1276-88. doi: 10.1158/1535-7163.MCT-11-0161. Epub 2011 May 17.


Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway.

Brown SA, Ghosh A, Winkles JA.

J Biol Chem. 2010 Jun 4;285(23):17432-41. doi: 10.1074/jbc.M110.131979. Epub 2010 Apr 12.


Progressive ankylosis protein (ANK) in osteoblasts and osteoclasts controls bone formation and bone remodeling.

Kim HJ, Minashima T, McCarthy EF, Winkles JA, Kirsch T.

J Bone Miner Res. 2010 Aug;25(8):1771-83. doi: 10.1002/jbmr.60.


Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function.

Fortin SP, Ennis MJ, Savitch BA, Carpentieri D, McDonough WS, Winkles JA, Loftus JC, Kingsley C, Hostetter G, Tran NL.

Mol Cancer Res. 2009 Nov;7(11):1871-81. doi: 10.1158/1541-7786.MCR-09-0194. Epub 2009 Oct 27.


Progressive ankylosis gene (ank) regulates osteoblast differentiation.

Kirsch T, Kim HJ, Winkles JA.

Cells Tissues Organs. 2009;189(1-4):158-62. doi: 10.1159/000151725. Epub 2008 Aug 26.


Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions.

Yang Y, Bai J, Shen R, Brown SA, Komissarova E, Huang Y, Jiang N, Alberts GF, Costa M, Lu L, Winkles JA, Dai W.

Cancer Res. 2008 Jun 1;68(11):4077-85. doi: 10.1158/0008-5472.CAN-07-6182.


The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity.

Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, Brown SA, Black MA, McDonough WS, Fortin SP, Niska JR, Winkles JA, Cunliffe HE.

Mol Cancer Res. 2008 May;6(5):725-34. doi: 10.1158/1541-7786.MCR-08-0005.


The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting.

Winkles JA.

Nat Rev Drug Discov. 2008 May;7(5):411-25. doi: 10.1038/nrd2488. Review.


The cytokine TWEAK modulates renal tubulointerstitial inflammation.

Sanz AB, Justo P, Sanchez-Niño MD, Blanco-Colio LM, Winkles JA, Kreztler M, Jakubowski A, Blanco J, Egido J, Ruiz-Ortega M, Ortiz A.

J Am Soc Nephrol. 2008 Apr;19(4):695-703. doi: 10.1681/ASN.2007050577. Epub 2008 Jan 30.


Inhibition of TWEAK activity as a new treatment for inflammatory and degenerative diseases.

Yepes M, Winkles JA.

Drug News Perspect. 2006 Dec;19(10):589-95. Review.


Role of TWEAK and Fn14 in tumor biology.

Winkles JA, Tran NL, Brown SA, Stains N, Cunliffe HE, Berens ME.

Front Biosci. 2007 Jan 1;12:2761-71. Review.


TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration.

Girgenrath M, Weng S, Kostek CA, Browning B, Wang M, Brown SA, Winkles JA, Michaelson JS, Allaire N, Schneider P, Scott ML, Hsu YM, Yagita H, Flavell RA, Miller JB, Burkly LC, Zheng TS.

EMBO J. 2006 Dec 13;25(24):5826-39. Epub 2006 Nov 23.


Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome.

Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, Nakada M, Cunliffe HE, Hostetter G, Hoelzinger DB, Rennert JL, Michaelson JS, Burkly LC, Lipinski CA, Loftus JC, Mariani L, Berens ME.

Cancer Res. 2006 Oct 1;66(19):9535-42.


Cytokine cooperation in renal tubular cell injury: the role of TWEAK.

Justo P, Sanz AB, Sanchez-Niño MD, Winkles JA, Lorz C, Egido J, Ortiz A.

Kidney Int. 2006 Nov;70(10):1750-8. Epub 2006 Sep 27.

Supplemental Content

Loading ...
Support Center